About syros pharmaceuticals inc - SYRS
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
SYRS At a Glance
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
Cambridge, Massachusetts 02140-2325
| Phone | 1-617-744-1340 | Revenue | 9.94M | |
| Industry | Biotechnology | Net Income | -164,574,000.00 | |
| Sector | Health Technology | Employees | 68 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
SYRS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 22.208 |
| Price to Book Ratio | 12.366 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.153 |
| Enterprise Value to Sales | 14.413 |
| Total Debt to Enterprise Value | 0.433 |
SYRS Efficiency
| Revenue/Employee | 146,117.647 |
| Income Per Employee | -2,420,205.882 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.048 |
SYRS Liquidity
| Current Ratio | 3.952 |
| Quick Ratio | 3.952 |
| Cash Ratio | 3.804 |
SYRS Profitability
| Gross Margin | 77.335 |
| Operating Margin | -1,273.138 |
| Pretax Margin | -1,656.341 |
| Net Margin | -1,656.341 |
| Return on Assets | -79.763 |
| Return on Equity | -227.945 |
| Return on Total Capital | -209.017 |
| Return on Invested Capital | -127.093 |
SYRS Capital Structure
| Total Debt to Total Equity | 372.554 |
| Total Debt to Total Capital | 78.838 |
| Total Debt to Total Assets | 36.911 |
| Long-Term Debt to Equity | 318.593 |
| Long-Term Debt to Total Capital | 67.419 |